Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Kom igång: Så börjar du spara i fonder 2025 – bästa tipsen för att komma igång (stor guide)

Pressmeddelande

Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET)

MFN Publicerad: 10 Apr 2023 08:30
2cureX

2cureX will have its Q1 2023 online presentation with a Q&A session on April 12, 2023 at 20.00 (CET).

2cureX Management will present status on the published goals for 2023 and additional important achievements.

From 2023 2cureX will be arranging a Q&A session (hosted by Stokk.io) shortly after the end of each quarter (Q1 on April 12) and a video commentary (hosted by Infront Direkt) on the same day we publish the quarterly report (Q1 report on May 25).

The new Q&A format allows you to submit questions already today or during the live event. You can sign up with link: Q&A webcast for Q1 2023).

The event will be livestreamed on the same link. The event is recorded and transcribed and made available for all investors afterwards on our website. 

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: [email protected]
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB, +46 8 121 576 90, [email protected]

Attachments

Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET)

Bifogade filer

Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET)https://storage.mfn.se/0672398c-3155-4327-8255-feadeb7ab1f7/invitation-to-2curex-q1-update-and-qanda-session-on-april-12-2023-at-20-00-cet.pdf

Nyheter om 2cureX

Läses av andra just nu

Om aktien 2cureX

Senaste nytt